3.05 USD
↘ 0.09 (2.87%)AT CLOSE (03:59 PM EST)
Galectin Therapeutics Inc.
GALTNASDAQ • USD
3.15
↗ 0.10 (3.12%)
POST MARKET (AS OF 04:14 PM EST)
Post Market
AS OF 04:14 PM EST
3.15
↗ 0.10 (3.12%)
Market: CLOSED
Galectin Therapeutics Inc. (GALT) trades at $3.05 per share. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (20.2%) and a bullish Golden Cross on the moving averages.
Technical & fundamental data as of Nov 13, 2026.
Open?$3.16
High?$3.31
Low?$2.93
Prev. Close?$3.14
Volume?181.6K
Avg. Volume?203.0K
VWAP?$3.02
Rel. Volume?0.89x
Bid / Ask
Bid?$2.95 × 300
Ask?$3.38 × 500
Spread?$0.43
Midpoint?$3.17
Valuation & Ratios
Market Cap?307.6M
Shares Out?100.8M
Float?66.9M
Float %?66.3%
P/E Ratio?N/A
P/B Ratio?-2.22
EPS?-$0.28
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Employees
9
Market Cap
316.7M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2002-09-04
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD
NORCROSS, GA 30071
Phone: 678-620-3186
NORCROSS, GA 30071
Phone: 678-620-3186
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?48
Piotroski F-Score?0/9Weak
Altman Z-Score?-55.54Distress
Confidence?59%Low
Short InterestVery High
Short % of Float?13.42%High
Short Interest?9.0M
Days to Cover?46.3
Free Float66.9M
Avg Daily Volume194.0K
Settlement Date2026-10-30
Financial Health
Current Ratio?0.10Weak
Quick Ratio?0.10Weak
Cash Ratio?0.09Low
Debt/Equity?-0.24Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-2.22CHEAP▾
S&P97
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-21.0CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?20.2%STRONG▾
Peers50
S&P66
ROA?-189.0%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-15889000
Enterprise Value?$327.4M
Fundamentals ratios updated end of day